Time filter

Source Type

Brno, Czech Republic

Pesova Z.,Oddeleni gynekologicke onkologie
Onkologie (Czech Republic) | Year: 2014

In the treatment of cervical cancer is the use of the three treatment modalities-surgery, radiotherapy and chemotherapy. Possible complications could appear at all modes. We can achieve early detection of signs of complications by intensive monitoring of patients undergoing treatment for cervical cancer. This will greatly increase the success rate of treatment. Source

Moukova L.,Oddeleni gynekologicke onkologie | Nenutil R.,Oddeleni Onkologicke Patologie | Fabian P.,Oddeleni Onkologicke Patologie | Chovanec J.,Oddeleni gynekologicke onkologie
Klinicka Onkologie | Year: 2013

Standardized gynecological oncological therapeutical guidelines are based on ordinary predictive factors, such as depth of stromal invasion, histopathological type of tumor, lymphovascular space invasion, lymph node metastases. Unfortunately, the power of these prognostic factors is not able to determine the safety of this procedure in the relation to disease recurrence in a group of patients who are indicated for conservative operations. This is the appropriate area for new, especially biomolecular prognostic factors (proteins: p63, TAp63, p16, p21, p27, COX-2, genes: hTERC, MYCC). Moreover, comprehensive evaluation of cervical cancer prognostic factors and assessment of new biomarkers of cancer can ease prediction of risk of spread outside primary localization and determine probability of disease recurrence. This information can help to individualize surgical, radiotherapeutic and chemotherapeutic treatment. Source

Chovanec J.,Oddeleni gynekologicke onkologie | Nalezinska M.,Oddeleni gynekologicke onkologie
Onkologie (Czech Republic) | Year: 2014

Three types of standard treatment of cervical cancer are used: surgery, radiation therapy, chemotherapy. New types of treatment are being tested in clinical trials. Treatment decisions should be individualized and based on prognostic factors including the stage of the disease, age, medical condition of the patient, histological type and grade of tumor and lymph nodes status. Source

Feranec R.,Oddeleni gynekologicke onkologie | Moukova L.,Oddeleni gynekologicke onkologie
Klinicka Onkologie | Year: 2013

In comparison to malignant tumors of vulva, vagina, cervix and uterine corpus, clear morphologic and molecular genetic features of precursor lesions of ovarian carcinoma have not been defined yet. We can see an effort to describe preinvasive lesions to allow diagnostics and treatment prior to development of invasive ovarian cancer. This tendency is magnified by the fact that ovarian carcinomas have the highest mortality from all gynecological malignancies. Currently, reports confirming different morphology, pathogenesis and molecular alterations in heterogeneous group of ovarian carcinomas have been described. There is a tendency to divide epithelial malignant tumors into two groups . Low-grade ovarian serous carcinoma, low-grade endometrioid, clear-cell, mucinous ovarian cancers and Brenner tumors of ovary are categorized as type I ovarian tumors. High-grade serous carcinoma, undifferentiated carcinomas and malignant mixed mesodermal tumors of the ovary (MMMTs) belong to type II tumors. A potential precursor lesion of high-grade serous ovarian cancer has been defined - serous tubal intraepithelial carcinoma. Source

Feranec R.,Oddeleni gynekologicke onkologie | Moukova L.,Oddeleni gynekologicke onkologie | Stanicek J.,Oddeleni Nuklearni Mediciny | Stefanikova L.,Oddeleni gynekologicke onkologie | Chovanec J.,Oddeleni gynekologicke onkologie
Klinicka Onkologie | Year: 2010

Backgrounds: Endometrial carcinoma is the most frequent gynecologic malignancy. The incidence is 30:100,000 with an increasing tendency. The main therapeutic modality remains radical surgery. The purpose of the study is to evaluate the feasibility of sentinel lymph node (SLN) detection in endometrial cancer using hysteroscopic administration of radiocolloid and the combination of preoperative lymphoscintigraphy with intraoperative gamma-detection probe examination. Patients and Methods: From May 2006 to January 2009, 99mTc-labelled nanocolloid (100 MBq) was administered preoperatively in 21 patients with endometrial cancer. On the day of surgery, radiocolloid together with blue dye was injected via 20-gauge needle under the endometrium using hysteroscopy. Lymphoscintigraphy was performed in all patients after 60 minutes. Therapeutic surgery followed the tracer administration 2 hours later in extensity of abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal wash, pelvic lymphadenectomy and in patients with positive high-risk prognostic factors of paraaortic lymphadenectomy. SLN was located by use of gamma-detecting probe intraoperatively. Results: At least one SLN was detected in 17 of 21 (81%) patients included in the study. The mean number of detected SLNs was 2 (range 1-5). 8 of 17 (47%) patients had radioactive nodes only in the paraaortic area. Synchronic appearance of SLNs in the pelvic and paraaortic areas was detected in 1 of 17 (6%) cases. Overall, in 4 of 9 (44%) cases of sentinel lymph node localization in the paraaortic area the SLNs were detected at the level above the inferior mesenteric artery. The metastatic involvement of 3 sentinel lymph nodes was detected in one patient (3 lymph nodes with micrometastases). All the remaining lymph nodes not labelled as SLNs were histologically negative in this case. The sensitivity and specificity for SLN metastases detection was 100%. Conclusion: SLN detection in endometrial cancer appears to be a promising method with the potential to reduce unnecessary surgery radicality and to clarify staging. The utilization of hysteroscopic application of radiocolloid respects the anatomical consequences and natural lymphatic drainage of the endometrium. The combination of pre-operative lymphoscintigraphy and intra-operative detection using a handheld gamma probe can be beneficial. Source

Discover hidden collaborations